What is Quotient Switzerland?
Founded in 1998, Quotient Switzerland operates at the intersection of advanced biotechnology and clinical diagnostics. The company is best known for its MosaiQ platform, a proprietary multiplex microarray technology that provides a fully automated, consolidated testing solution. By enabling multiple tests across diverse modalities on a single platform, Quotient addresses critical inefficiencies in laboratory settings, offering significant cost savings and improved clinical outcomes.
Beyond its core transfusion diagnostics portfolio, the company has demonstrated agility in responding to global health crises, notably through the development of the MosaiQ COVID-19 Antibody Microarray. This product, which has secured both CE marking and U.S. FDA Emergency Use Authorization, highlights the company's capability to pivot its technological infrastructure to address urgent diagnostic needs while maintaining its long-term focus on reshaping the standard of care in transfusion medicine.
How much funding has Quotient Switzerland raised?
Quotient Switzerland has raised a total of $219M across 3 funding rounds:
Stock Offering
$40M
Debt
$84M
Stock Offering
$95M
Stock Issuance/Offering (2014): $40M, investors not publicly disclosed
Debt (2016): $84M led by Morgan Stanley & Co. LLC
Stock Issuance/Offering (2021): $95M, investors not publicly disclosed
Key Investors in Quotient Switzerland
Morgan Stanley & Co. LLC
A global financial services firm providing investment banking, securities, and wealth management services to a diverse client base.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Quotient Switzerland?
With the recent strategic investment, Quotient is well-positioned to expand the market penetration of its MosaiQ platform. The company's roadmap likely involves scaling manufacturing capabilities to meet global demand and further diversifying its diagnostic menu to include additional clinical modalities. As the diagnostics industry shifts toward greater automation and consolidation, Quotient's ability to deliver workflow improvements will be a key driver of its long-term valuation.
Investors are closely monitoring the company's ability to translate its technological innovation into sustained revenue growth. The focus will remain on operational execution and the successful integration of its diagnostic solutions into high-volume laboratory networks, ensuring that the firm remains a leader in the competitive landscape of medical technology.
